Aetna gets antitrust suit moved back to state court
25-04-2022
Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS
16-02-2021
Russian drugmakers bypass Gilead to unveil COVID-19 generic
04-02-2021
Sundry Photography / Shutterstock.com
Gilead Sciences has failed to prevent insurer Aetna from pursuing its lawsuit in a US state court, as it faces a spate of antitrust complaints alleging that it used pay-for-delay deals to maintain the high costs of HIV drugs.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Gilead, Aetna, Teva, Humana, Blue Cross Shield, HIV, Antitrust
